Use of FLT3 CAR-T cells and FLT3 inhibitors to treat acute myeloid leukemia

摘要

The present invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the present invention relates to adoptive immunotherapy for acute myeloid leukemia (AML) in which FMS-like tyrosine kinase (FLT3) -specific chimeric antigen receptor (CAR) -modified T cells are used in combination with FLT3 inhibitors.